Hematopathology

Product Information

Another exciting aspect of my current work is educating young pathologists; sitting across the microscope from them and helping them develop their skills, and then also helping them develop their careers,” Dr. Jaffe said. Her lab's findings led to the development of the WHO Classification of Tumours of the Hematopoietic and Lymphoid Tissues. [4] Jaffe was the President of the Society of Hematopathology at the time that the WHO's Revised European-American Classification of Lymphoid Neoplasms (REAL) classification system was developed in 1994; the REAL classification system is now considered the gold standard in hematopathology. [5] Today, her research includes genetic and epigenetic studies aimed at understanding how B-cells become Hodgkin's lymphoma cells, particularly through the lens of the microenvironment. [2] Jaffe's research has led to improvements in cancer treatments, including disease-specific therapies and improved clinical outcomes. [6] Early life and career development [ edit ] Griffiths, R.; Mikhael, J.; Gleeson, M.; Danese, M.; Dreyling, M. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood 2011, 118, 4808–4816. [ Google Scholar] [ CrossRef]

She served as president of the Society for Hematopathology and the United States and Canadian Academy of Pathology (USCAP). As the Vietnam War trudged on, Dr. Jaffe’s family grew and the clan headed for Washington, DC, where she took a residency position at Georgetown University and worked primarily in anatomic pathology.

Elaine Jaffe Puts Lymphomas in Their Place

Ladetto, M.; Cortelazzo, S.; Ferrero, S.; Evangelista, A.; Mian, M.; Tavarozzi, R.; Zanni, M.; Cavallo, F.; Di Rocco, A.; Stefoni, V.; et al. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: Results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. Lancet Haematol. 2021, 8, e34–e44. [ Google Scholar] [ CrossRef]

Primary cutaneous B-cell lymphomas (PCBCLs) account for 25% of all primary cutaneous lymphomas. Three major types are currently recognized by the WHO classification: primary cutaneous marginal zone B-cell lymphoma (PCMZL), primary cutaneous follicle centre lymphoma (PCFCL) (both considered indolent lymphomas) and primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT), which is, instead, a very aggressive disease. Nowadays, the PCBCL’s category also includes some rare entities such as intravascular B-cell lymphoma (IVBL) and the EBV+ mucocutaneous ulcer (EBVMCU). Furthermore, controversies still exist concerning the category of primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), because some cases may present with clinical and histological features between PCFCL and PCDLBCL-LT. Therefore, some authors proposed introducing another category called PCDLBCL, not otherwise specified (NOS). Regardless, PCBCLs exhibit distinct features and differ in prognosis and treatment from their nodal/systemic counterparts. Therefore, clinicopathologic analysis is a key diagnostic element in the work-up of these lymphomas. LaCasce, A.S.; Vandergrift, J.L.; Rodriguez, M.A.; Abel, G.A.; Crosby, A.L.; Czuczman, M.S.; Nademanee, A.P.; Blayney, D.W.; Gordon, L.I.; Millenson, M.; et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: An analysis from the NCCN NHL Database. Blood 2012, 119, 2093–2099. [ Google Scholar] [ CrossRef] [ PubMed] In one of her earliest articles, a Citation Classic ( N Engl J. Med l974; 290: 8l3–8l9), Dr Jaffe showed evidence of follicular lymphoma origin from normal follicular B cells. Since then, she has unveiled many pathologically and clinically relevant “guises and disguises” of follicular lymphoma. She described in situ follicular lymphoma, offering clues about the initial genetic changes in follicular lymphomagenesis. She identified histiocytic/dendritic cell tumors occurring with follicular lymphoma, providing the first evidence for the lineage plasticity of mature lymphoid cells. Understanding the genetic and epigenetic events involved in mediastinal B-cell lymphoma biology and, in particular, the mechanisms that cause a B-cell to become a Hodgkin cell and the role of tumor cell interaction with the microenvironment also engaged Dr. Jaffe’s research interest.

Vandenberghe, E.; Ruiz de Elvira, C.; Loberiza, F.R.; Conde, E.; Lopez-Guillermo, A.; Gisselbrecht, C.; Guihot, F.; Vose, J.M.; van Biesen, K.; Rizzo, J.D.; et al. Outcome of autologous transplantation for mantle cell lymphoma: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br. J. Haematol. 2003, 120, 793–800. [ Google Scholar] [ CrossRef] [ PubMed] Ruan, J.; Martin, P.; Christos, P.; Cerchietti, L.; Tam, W.; Shah, B.; Schuster, S.J.; Rodriguez, A.; Hyman, D.; Calvo-Vidal, M.N.; et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Blood 2018, 132, 2016–2025. [ Google Scholar] [ CrossRef] [ PubMed] Armitage, J.O.; Weisenburger, D.D. New approach to classifying non-Hodgkin’s lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J. Clin. Oncol. 1998, 16, 2780–2795. [ Google Scholar] [ CrossRef] [ PubMed]